Lifecore Biomedical, Inc. LFCR
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | 05/25/2025 | |
|---|---|---|---|---|---|
| Net Income | -436.70% | -1.43% | 38.44% | 38.44% | 83.81% |
| Total Depreciation and Amortization | 31.40% | 11.27% | -0.60% | -0.60% | -4.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.06% | -27.20% | 49.08% | 49.08% | -39.99% |
| Change in Net Operating Assets | -731.38% | 324.55% | -91.46% | -91.46% | -123.09% |
| Cash from Operations | -140.94% | 291.67% | 374.03% | 374.03% | -38.65% |
| Capital Expenditure | 75.54% | 79.51% | 48.79% | 48.79% | 22.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 75.54% | -172.41% | 48.79% | 48.79% | 22.71% |
| Total Debt Issued | -78.22% | -- | 532.18% | 532.18% | -12.23% |
| Total Debt Repaid | 78.10% | -484.18% | -5,192.70% | -5,192.70% | 12.55% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -259.06% | -- | -96.26% | -96.26% | 77.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.41% | 41.15% | -- | -- | -858.76% |
| Cash from Financing | -111.94% | 96.23% | -226.99% | -226.99% | 34.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.79% | 182.37% | 53.67% | 53.67% | -47.15% |